Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

PloS one - 1 Jan 2012

Ho Alan L, Musi Elgilda, Ambrosini Grazia, Nair Jayasree S, Deraje Vasudeva Shyamprasad, de Stanchina Elisa, Schwartz Gary K

Abstract excerpt

Uveal melanomas possess activation of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT/mammalian Target of Rapamycin (mTOR) pathways. MAPK activation occurs via somatic mutations in the heterotrimeric G protein subunits GNAQ and GNA11 for over 70% of tumors and less frequently via V600E BRAF mutations. In this report, we describe the impact of dual pathway inhibition upon uveal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GTP-Binding Protein alpha Subunits
Share to GTP-Binding Protein alpha Subunits, Gq-G11

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 2

Share to Morpholines

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Receptor, IGF Type 1

Share to Uveal Melanoma

Share to Uveal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 22808163
DOI: 10.1371/journal.pone.0040439
PMCID: PMC3393714

Genes

BRAF
GNAQ
GNA11

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.PMID 22808163Read ↗

Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.Semantic proximity Read ↗

Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.Semantic proximity Read ↗

Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).Semantic proximity Read ↗

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibSemantic proximity Read ↗

Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK ResistanceSemantic proximity Read ↗

The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.Semantic proximity Read ↗

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.Semantic proximity Read ↗

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.Semantic proximity Read ↗

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.Semantic proximity Read ↗

Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.Semantic proximity Read ↗

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.Semantic proximity Read ↗

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.